Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:"Clinical use of biomarkers of survival in pulmonary fibrosis. | Thomeer et al. Respiratory Research 2010 11 89 http content 11 1 89 REVIEW RESPIRATORY RESEARCH Open Access Clinical use of biomarkers of survival in pulmonary fibrosis 12 34 2 5 2 Michiel Thomeer1 Jan C Grutters Wim A Wuyts Stijn Willems Maurits G Demedts Abstract Background Biologic predictors or biomarkers of survival in pulmonary fibrosis with a worse prognosis more specifically in idiopathic pulmonary fibrosis would help the clinician in deciding whether or not to treat since treatment carries a potential risk for adverse events. These decisions are made easier if accurate and objective measurements of the patients clinical status can predict the risk of progression to death. Method A literature review is given on different biomarkers of survival in interstitial lung disease mainly in IPF since this disease has the worst prognosis. Conclusion Serum biomarkers and markers measured by medical imaging as HRCT pertechnegas DTPA en FDG-PET are not ready for clinical use to predict mortality in different forms of ILD. A baseline FVC a change of FVC of more than 10 and change in 6MWD are clinically helpful predictors of survival. Introduction Interstitial lung diseases ILD 1 are a heterogeneous group of lung diseases that comprise more than 200 clinical pathological entities. Although clinically the different ILD have rather similar presentations with increasing shortness of breath a restrictive lung function impaired gas exchange and a widespread shadowing on the chest radiograph they comprise a very wide spectrum of pathologies clinical manifestations and outcomes. Approximately two-thirds of ILD cases have no reported aetiology 2 . The remaining one-third is associated with or defined by various environmental or occupational factors including cigarette smoking aspiration certain drugs and radiation therapy 3 4 . Despite their acknowledged complexity there is little evidence about the best management of ILD. Morbidity of the ILD themselves
